Compare MCFT & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | DMAC |
|---|---|---|
| Founded | 1968 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.1M | 347.5M |
| IPO Year | 2015 | 2018 |
| Metric | MCFT | DMAC |
|---|---|---|
| Price | $22.50 | $5.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $24.25 | $15.50 |
| AVG Volume (30 Days) | ★ 158.0K | 134.4K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $284,203,000.00 | $500,000.00 |
| Revenue This Year | $9.18 | N/A |
| Revenue Next Year | $8.23 | N/A |
| P/E Ratio | $66.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.19 | $3.48 |
| 52 Week High | $28.44 | $10.42 |
| Indicator | MCFT | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 40.24 |
| Support Level | $21.94 | $5.30 |
| Resistance Level | $24.01 | $7.31 |
| Average True Range (ATR) | 0.86 | 0.31 |
| MACD | -0.23 | -0.02 |
| Stochastic Oscillator | 26.76 | 19.70 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.